2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.
Investor Overview
2019 Q2 Financial Results
available 4.01pm (EST)
Wednesday, August 7, 2019
Financial Report Archives
2019 Financial Reports
- Q1
- Q2
- Q3
- Q4
News Release Archives
2019 News Releases
Share Information
Auditor
Grant Thornton LLP, Vancouver, BC
Legal Counsel
Blakes LLP, Vancouver, BC
Transfer Agent
Computershare, Vancouver, BC
Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com
To automatically receive news updates